Bayer AG NA (BAYN HM) stock market data APIs
€27.283
-0.6(-2.2%)
as of July 14, 2025
Try our APIs with
free plan!
Bayer AG NA Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for BAYN.HM.
Prev. Close
27.283
Open
26.6876
High
27.283
Low
26.6876
52 wk Range
18.605-30.6832
Market Cap
45 791 M
EPS
1.22
Dividends (Yield)
0.0497
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Bayer AG NA data using free add-ons & libraries
Get Bayer AG NA Fundamental Data
Bayer AG NA Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2023-08-08
- EPS/Forecast: 1.26
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Bayer AG NA News
New
Connecticut wants to make generic GLP-1s. Will RFK Jr. lend a hand?
Connecticut passed a new law last week in an effort to lower its spending on weight-loss drugs for its state insurance program — HUSKY Health, which includes Medicaid and CHIP enrollees — and it c...
Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings?
Novartis AG NVS, a Swiss pharma giant, is scheduled to report second-quarter 2025 results on July 17. The Zacks Consensus Estimate for revenues is pegged at $14.04 billion, while the same for earning...
AstraZeneca Meets All Key Goals in Phase III Hypertension Study
AstraZeneca AZN reported positive top-line results from a late-stage study evaluating the safety, tolerability and efficacy of its investigational candidate, baxdrostat, in patients with uncontrolled ...
Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA
Ultragenyx Pharmaceuticals RARE announced that the FDA has issued a Complete Response Letter (CRL) for its biologics license application (BLA) for UX111. The AAV gene therapy is being developed as a t...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
